logo
Plus   Neg
Share
Email

FUCHS Sells 50% Share In MOTOREX AG Langenthal For CHF 17 Mln

The FUCHS Group sold its 50% share in MOTOREX AG Langenthal, founded in 1973, for 17 million Swiss francs to the former local partner, MOTOREX-BUCHER Group AG in Langenthal.

Over the past four decades, FUCHS PETROLUB and MOTOREX-BUCHER have grown strongly both nationally and internationally. Both companies are grateful for the former partnership but intend to go separate ways in the future, FUCHS said.

FUCHS said it will participate in the Swiss market directly and with trading partners under the FUCHS brand in the future.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>